Abeona Therapeutics (ABEO)

Abeona Therapeutics (ABEO) Income Statement


Abeona Therapeutics Income Statement

Last quarter (Q1 2023), Abeona Therapeutics's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q1, Abeona Therapeutics's net income was $14.97M. See Abeona Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 1.07M$ 1.41M$ 3.00M$ 10.00M$ 0.00$ 3.00M
Cost of Revenue
$ -100.00K$ -450.00K----
Gross Profit
$ 859.00K$ 1.55M----
Operating Expense
$ -5.54M$ -52.33M$ 60.37M$ 58.50M$ 77.09M$ 61.16M
Operating Income
$ -21.48M$ -46.91M$ -57.37M$ -48.50M$ -77.09M$ -58.17M
Net Non Operating Interest Income Expense
$ -564.00K$ -736.00K$ -3.60M$ -2.81M$ 808.00K$ 1.50M
Other Income Expense
$ -13.19M$ -7.52M$ -23.96M$ -32.92M--
Pretax Income
$ -3.85M$ -39.70M$ -84.94M$ -84.23M$ -76.28M$ -56.67M
Tax Provision
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -7.63M$ -43.48M$ -84.94M$ -84.23M$ -76.28M$ -56.67M
Basic EPS
$ -5.93$ -5.53$ -21.50$ -0.91$ -1.51$ -1.19
Diluted EPS
$ -3.56-$ -21.50$ -0.91$ -1.51$ -1.19
Basic Average Shares
$ 36.99M$ 7.86M$ 3.94M$ 92.66M$ 50.35M$ 47.53M
Diluted Average Shares
$ 12.23M-$ 3.94M$ 92.66M$ 50.35M$ 47.53M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ -5.64M$ -52.78M$ 60.37M$ 58.50M$ 77.09M$ 61.16M
Net Income From Continuing And Discontinued Operation
$ -27.93M$ -39.70M$ -84.94M$ -84.23M$ -76.28M$ -56.67M
Normalized Income
$ -19.24M-$ -60.97M$ -51.32M$ -76.28M$ -56.67M
Interest Expense
$ 474.00K-$ 3.67M$ 4.12M$ 400.00K$ 11.00K
$ -3.19M$ -38.96M$ -81.27M$ -80.12M$ -75.88M$ -56.66M
$ -659.00K$ -42.06M$ -76.80M$ -74.52M$ -67.20M$ -54.30M
Currency in USD

Abeona Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis